{
    "root": "2f74f2c5-c71e-d877-e063-6394a90a471d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "venlafaxine",
    "value": "20250303",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "VENLAFAXINE HYDROCHLORIDE",
            "code": "7D7RX5A8MO"
        }
    ],
    "indications": "venlafaxine tablets , usp indicated treatment major depressive disorder . efficacy venlafaxine tablets , usp treatment major depressive disorder established 6-week controlled trials adult outpatients whose diagnoses corresponded closely dsm-iii dsm-iii-r category major depression 4-week controlled trial inpatients meeting diagnostic criteria major depression melancholia ( trials ) . major depressive episode implies prominent relatively persistent depressed dysphoric mood usually interferes daily functioning ( nearly every day least 2 weeks ) ; include least 4 following 8 symptoms : change appetite , change sleep , psychomotor agitation retardation , loss interest usual activities decrease sexual drive , increased fatigue , feelings guilt worthlessness , slowed thinking impaired concentration , suicide attempt suicidal ideation . efficacy venlafaxine hydrochloride extended-release capsules maintaining antidepressant response 26 weeks following 8 weeks acute treatment demonstrated placebo-controlled trial . efficacy venlafaxine tablets , usp maintaining antidepressant response patients recurrent depression responded continued improved initial 26 weeks treatment followed period 52 weeks demonstrated second placebo-controlled trial ( trials ) . nevertheless , physician elects venlafaxine tablets , usp/venlafaxine hydrochloride extended-release capsules extended periods periodically re-evaluate long-term usefulness individual patient .",
    "contraindications": null,
    "warningsAndPrecautions": "venlafaxine tablets usp , 100 mg peach colored , circular , biconvex , uncoated tablets debossed ' ' breakline one side '22 ' side . ndc : 70518-1976-00 packaging : 30 1 blister pack store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] dry place . dispense well-closed container defined usp . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "hypersensitivity venlafaxine hydrochloride excipients formulation . maois intended treat psychiatric disorders venlafaxine tablets within 7 days stopping treatment venlafaxine tablets contraindicated increased risk serotonin syndrome . venlafaxine tablets within 14 days stopping maoi intended treat psychiatric disorders also contraindicated ( ) . starting venlafaxine tablets patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome ( ) .",
    "indications_original": "Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. \n  \n                       The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see\n \n  \n                        \n                           CLINICAL TRIALS\n                        \n                     ). \n  \n                       A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. \n  \n                       The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets, USP in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see\n \n  \n                        \n                           CLINICAL TRIALS\n                        \n                     ). Nevertheless, the physician who elects to use venlafaxine tablets, USP/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.",
    "warningsAndPrecautions_original": "Venlafaxine Tablets USP, 100 mg are peach colored, circular, biconvex, uncoated tablets debossed with 'I' and breakline on one side and '22' on the other side.\n                  NDC: 70518-1976-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] in a dry place.\n                  \n                  Dispense in a well-closed container as defined in the USP.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Hypersensitivity to venlafaxine hydrochloride or to any excipients in the formulation.\n                  \n                  The use of MAOIs intended to treat psychiatric disorders with venlafaxine tablets or within 7 days of stopping treatment with venlafaxine tablets is contraindicated because of an increased risk of serotonin syndrome. The use of venlafaxine tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see \n \n  \n                        WARNINGS\n                     and \n \n  \n                        DOSAGE AND ADMINISTRATION\n                     ).\n\n \n                  \n                  Starting venlafaxine tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see\n \n  \n                        \n                           \n                              WARNINGS\n                           \n                        \n                      and \n \n  \n                        DOSAGE AND ADMINISTRATION\n                     )."
}